• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cannabis Stocks: Canadian Companies Outperformed American Counterparts Last Week

    7/16/24 6:25:22 PM ET
    $ACB
    $CGC
    $CRON
    $OGI
    Medicinal Chemicals and Botanical Products
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email

    Analyst Lorimer Wilson, a contributor at TalkMarkets, signaled that Canadian Limited Partnership (LPs) Cannabis Companies did much better than American multi-state operators (MSOs) as the cannabis sector remains highly volatile, with stock prices reacting sharply to news.

    Canadian Cannabis Outperforms

    Canadian Cannabis LPs doubled the performance of cannabis companies from the US. The Canadian Cannabis LP Portfolio saw significant gains:

    • Aurora Cannabis (NASDAQ:ACB): UP 24.7% this week; UP 30.1% MTD; UP 27.3% YTD
    • Tilray Brands (NASDAQ:TLRY): UP 8.7% this week; UP 13.3% MTD; DOWN 18.3% YTD
    • Cronos Group (NASDAQ:CRON): UP 8.1% this week; UP 3.4% MTD; UP 15.3% YTD
    • Organigram (NASDAQ:OGI): UP 6.9% this week; UP 10.4% MTD; UP 29.8% YTD
    • Canopy Growth (NASDAQ:CGC): UP 2.4% this week; UP 0.6% MTD; UP 27.0% YTD

    On average, the LP Portfolio was UP 10.7% this week, 11.4% MTD, and 17.5% YTD.

    Read Also: Why The Time To Invest In U.S. Cannabis Stocks Is Right Now

    American Cannabis Performance

    The American Cannabis MSO Portfolio showed modest gains in comparison:

    • Curaleaf (OTC:CURLF): UP 10.2% this week; UP 9.6% MTD; UP 1.7% YTD
    • Cresco Labs (OTC:CRLBF): UP 9.0% this week; UP 7.6% MTD; UP 25.9% YTD
    • Ayr Wellness (OTC:AYRWF): UP 8.4% this week; UP 4.6% MTD; UP 14.4% YTD
    • Trulieve Cannabis (OTC:TCNNF): UP 7.8% this week; UP 8.0% MTD; UP 91.6% YTD
    • Verano (OTC:VRNOF): UP 5.1% this week; UP 1.4% MTD; DOWN 16.5% YTD
    • TerrAscend (OTC:TSNDF): UP 1.5% this week; DOWN 0.7% MTD; DOWN 17.8% YTD
    • Green Thumb (OTC:GTBIF): UP 0.9% this week; DOWN 1.8% MTD; UP 2.7% YTD

    On average, the MSO Portfolio increased by 5.2% this week, 3.4% MTD and 15.9% YTD.

    Cannabis Stock Market Insights

    The 12 largest cannabis stocks were UP 7.0% last week, UP 6.0% MTD, and UP 16.5% YTD. Wilson’s observations highlight the strong performance of Canadian LPs, offering investors a promising outlook.

    Fundamental analysis indicates that American cannabis companies have way more space to grow when it comes to valuation and are also more profitable. Nevertheless, disincentives related to the legislative framework and regulation are putting a limit on their growth capacities. Should some of the main regulations change, such as the rescheduling of cannabis or banking limitations, the chance for growth is promising.

    The U.S. cannabis market presents a significant risk-reward opportunity, particularly for MSOs. Despite market volatility and challenges, the fundamental growth potential and increasing public support make U.S. MSOs a compelling long-term investment.

    • Read Next: Canadian Cannabis Companies Are More Valuable Than Rivals In The U.S. – Here’s Why

    These issues will be a hot topic at the upcoming Benzinga Cannabis Capital Conference in Chicago this Oct. 8-9. Join us to get more insight into what the wave of weed legalization means for the future of investing in the industry. Hear directly from top executives, investors, advocates, and policymakers. Get your tickets now before prices go up by following this link.

    Cover: AI generated

    Get the next $ACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB
    $CGC
    $CRON
    $OGI

    CompanyDatePrice TargetRatingAnalyst
    Tilray Brands Inc.
    $TLRY
    4/3/2026$10.00Neutral → Buy
    Roth Capital
    Tilray Brands Inc.
    $TLRY
    4/2/2026$10.00Neutral → Buy
    Roth Capital
    Canopy Growth Corporation
    $CGC
    3/27/2026Buy
    Canaccord Genuity
    Tilray Brands Inc.
    $TLRY
    1/27/2026Hold
    Canaccord Genuity
    Aurora Cannabis Inc.
    $ACB
    1/27/2026Buy
    Canaccord Genuity
    Organigram Global Inc.
    $OGI
    1/27/2026Buy
    Canaccord Genuity
    Cronos Group Inc.
    $CRON
    1/27/2026Buy
    Canaccord Genuity
    Canopy Growth Corporation
    $CGC
    11/10/2025Sell → Hold
    The Benchmark Company
    More analyst ratings

    $ACB
    $CGC
    $CRON
    $OGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Yanofsky Theresa

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:16:22 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Atkins M Shan

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:16:02 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Bayern Joseph

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:15:39 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $CGC
    $CRON
    $OGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram") and Sanity Group GmbH ("Sanity" or "Sanity Group") jointly announced the successful closing of Organigram's previously announced acquisition (the "Acquisition") of Sanity Group, pursuant to the terms of a share purchase agreement dated February 18, 2026 (the "Share Purchase Agreement"). In connection with closing of the Acquisition, a wholly owned subsidiary of the Company acquired all of the issued and outstanding shares of Sanity Group not already owned by the Company for an upfront purchase price paid on closing of €107.3 million, consisting of €78.0 million in cash and €29.3 million in share consideration (th

    4/15/26 12:03:00 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership

    NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today announced a series of strategic initiatives marking its next phase of global growth, expanding its leadership across healthcare, cannabis and beverage while strengthening its ability to expand internationally and capture emerging market opportunities. Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, stated: "Tilray Brands is setting the pace for global innovation across healthcare, cannabi

    4/15/26 7:40:44 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International Markets

    NASDAQ | TSX: ACBEDMONTON, AB, April 15, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is pleased to announce it has acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5 million, subject to customary adjustments, and inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions (the "Transaction"). "The acquisition of Safari Flower Company marks an impor

    4/15/26 7:05:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $CGC
    $CRON
    $OGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Global General Counsel Gendel Mitchell exercised 93,928 shares at a strike of $0.58, covered exercise/tax liability with 49,782 shares and bought $3,496 worth of shares (6,000 units at $0.58), increasing direct ownership by 8% to 698,287 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:19 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 6:52:32 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $CGC
    $CRON
    $OGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tilray upgraded by Roth Capital with a new price target

    Roth Capital upgraded Tilray from Neutral to Buy and set a new price target of $10.00

    4/3/26 10:44:58 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray upgraded by Roth Capital with a new price target

    Roth Capital upgraded Tilray from Neutral to Buy and set a new price target of $10.00

    4/2/26 7:55:13 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity initiated coverage on Canopy Growth

    Canaccord Genuity initiated coverage of Canopy Growth with a rating of Buy

    3/27/26 8:46:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $CGC
    $CRON
    $OGI
    SEC Filings

    View All

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    4/16/26 4:18:36 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    4/15/26 7:50:19 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Tilray Brands Inc.

    424B5 - Tilray Brands, Inc. (0001731348) (Filer)

    4/15/26 9:13:28 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $CGC
    $CRON
    $OGI
    Leadership Updates

    Live Leadership Updates

    View All

    Organigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special Meeting

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), is pleased to announce that the shareholders of Organigram have overwhelmingly approved the resolution required to consummate the previously announced acquisition by the Company (the "Transaction") of Sanity Group GmbH ("Sanity Group") and the related private placement financing (the "Private Placement") with BT DE Investments Inc., a wholly-owned subsidiary of British American Tobacco ("BAT") at the Company's annual general and special meeting of shareholders (the "Shareholders") held on March 30, 2026 (the "Meeting"). Shareholders approved an ordinary resolution (the "Transaction Resolution") authorizing (i)

    3/30/26 8:30:00 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH

    ISS Cites Compelling Strategic Rationale, Favorable Market Reaction, and Strong Institutional Confidence in Recommending Shareholders Vote FOR the Transaction Resolution Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended that holders of common shares of Organigram ("Shareholders") vote FOR the ordinary resolution (the "Transaction Resolution") to approve the indirect acquisition of Sanity Group GmbH ("Sanity") at the Company's Annual General and Special Meeting of Shareholders (the "Mee

    3/23/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $CGC
    $CRON
    $OGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    12/10/24 7:10:15 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    9/3/24 9:30:26 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    4/25/24 6:39:55 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $CGC
    $CRON
    $OGI
    Financials

    Live finance-specific insights

    View All

    Tilray Brands to Announce Third Quarter Fiscal Year 2026 Financial Results on April 1, 2026

    NEW YORK and LEAMINGTON, Ontario, March 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the third fiscal quarter which ended February 28, 2026, before the financial markets open on Wednesday, April 1, 2026. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 8:30 AM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of Ti

    3/25/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Acquires BrewDog Australia, Establishing Strategic Base to Accelerate Global Beverage and Consumer Products Growth Across the Asia-Pacific Region

    Acquisition Includes BrewDog's Profitable Australian Operations Including Brisbane Brewery and Two Flagship Bars Transaction Positions Tilray to Scale BrewDog Across Australia's National Retail and Grocery Channels and Introduce Broader Beverage Portfolio Across Asia-Pacific NEW YORK and BRISBANE, Australia, March 09, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced the completion of the acquisition of BrewDog Brewing Australia Pty Ltd., including BrewDog's Australian brewing and pr

    3/9/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform

    Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs  Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - $8 Million of Adjusted EBITDA in Fiscal 2027 Tilray's Global Consolidated Net Revenue Expected to Reach ~$1.2 Billion on an Annualized Basis1 Conference Call Scheduled for 12:30pm ET NEW YORK and LONDON, March 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today completed the acquisition of certain highly strategic

    3/2/26 10:17:01 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care